315 related articles for article (PubMed ID: 28664935)
1. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease.
Garces S; Medeiros LJ; Patel KP; Li S; Pina-Oviedo S; Li J; Garces JC; Khoury JD; Yin CC
Mod Pathol; 2017 Oct; 30(10):1367-1377. PubMed ID: 28664935
[TBL] [Abstract][Full Text] [Related]
2. Rosai-Dorfman Disease Harboring an Activating KRAS K117N Missense Mutation.
Shanmugam V; Margolskee E; Kluk M; Giorgadze T; Orazi A
Head Neck Pathol; 2016 Sep; 10(3):394-9. PubMed ID: 26922062
[TBL] [Abstract][Full Text] [Related]
3. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.
Chakraborty R; Hampton OA; Shen X; Simko SJ; Shih A; Abhyankar H; Lim KP; Covington KR; Trevino L; Dewal N; Muzny DM; Doddapaneni H; Hu J; Wang L; Lupo PJ; Hicks MJ; Bonilla DL; Dwyer KC; Berres ML; Poulikakos PI; Merad M; McClain KL; Wheeler DA; Allen CE; Parsons DW
Blood; 2014 Nov; 124(19):3007-15. PubMed ID: 25202140
[TBL] [Abstract][Full Text] [Related]
4. Focal Rosai-Dorfman disease coexisting with lymphoma in the same anatomic site: a localized histiocytic proliferation associated with MAPK/ERK pathway activation.
Garces S; Yin CC; Patel KP; Khoury JD; Manning JT; Li S; Xu J; Pina-Oviedo S; Johnson MR; González S; Molgó M; Ruiz-Cordero R; Medeiros LJ
Mod Pathol; 2019 Jan; 32(1):16-26. PubMed ID: 30323237
[TBL] [Abstract][Full Text] [Related]
5. Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations.
Pina-Oviedo S; Medeiros LJ; Li S; Khoury JD; Patel KP; Alayed K; Cason RC; Bowman CJ; Yin CC
Mod Pathol; 2017 May; 30(5):734-744. PubMed ID: 28084334
[TBL] [Abstract][Full Text] [Related]
6. How I Diagnose Rosai-Dorfman Disease.
Ravindran A; Rech KL
Am J Clin Pathol; 2023 Jul; 160(1):1-10. PubMed ID: 37167084
[TBL] [Abstract][Full Text] [Related]
7. MAP2K1-driven mixed Langerhans cell histiocytosis, Rosai-Dorfman-Destombes disease and Erdheim-Chester disease, clonally related to acute myeloid leukemia.
Bonometti A; Ferrario G; Parafioriti A; Giardino D; Simonetti F; Ginori A; Passoni E; Berti E;
J Cutan Pathol; 2021 May; 48(5):637-643. PubMed ID: 33188581
[TBL] [Abstract][Full Text] [Related]
8. Frequency of MAP2K1, TP53, and U2AF1 Mutations in BRAF-mutated Langerhans Cell Histiocytosis: Further Characterizing the Genomic Landscape of LCH.
McGinnis LM; Nybakken G; Ma L; Arber DA
Am J Surg Pathol; 2018 Jul; 42(7):885-890. PubMed ID: 29649018
[TBL] [Abstract][Full Text] [Related]
9. BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases.
Alayed K; Medeiros LJ; Patel KP; Zuo Z; Li S; Verma S; Galbincea J; Cason RC; Luthra R; Yin CC
Hum Pathol; 2016 Jun; 52():61-7. PubMed ID: 26980021
[TBL] [Abstract][Full Text] [Related]
10. Mutually exclusive extracellular signal-regulated kinase pathway mutations are present in different stages of multi-focal pulmonary Langerhans cell histiocytosis supporting clonal nature of the disease.
Kamionek M; Ahmadi Moghaddam P; Sakhdari A; Kovach AE; Welch M; Meng X; Dresser K; Tomaszewicz K; Cosar EF; Mark EJ; Fraire AE; Hutchinson L
Histopathology; 2016 Sep; 69(3):499-509. PubMed ID: 26915300
[TBL] [Abstract][Full Text] [Related]
11. Is Rosai-Dorfman disease a reactve process? Detection of a MAP2K1 L115V mutation in a case of Rosai-Dorfman disease.
Matter MS; Bihl M; Juskevicius D; Tzankov A
Virchows Arch; 2017 Oct; 471(4):545-547. PubMed ID: 28597077
[No Abstract] [Full Text] [Related]
12. Pediatric recurrent Rosai-Dorfman disease with germline heterozygous SLC29A3 and somatic MAP2K1 mutations.
Suryaprakash S; George A; Langenburg S; Savaşan S
Ann Hematol; 2020 Dec; 99(12):2965-2967. PubMed ID: 32944792
[No Abstract] [Full Text] [Related]
13. Recurrent central nervous system Rosai-Dorfman disease with KRAS mutation: a case report.
Wang Q; Ren H; Zheng L; Wang J; Zhong D
Diagn Pathol; 2023 Feb; 18(1):21. PubMed ID: 36782249
[TBL] [Abstract][Full Text] [Related]
14. Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Destombes-Rosai-Dorfman Disease): from Oncogenic Mutations to Inflammatory Disorders.
Papo M; Cohen-Aubart F; Trefond L; Bauvois A; Amoura Z; Emile JF; Haroche J
Curr Oncol Rep; 2019 May; 21(7):62. PubMed ID: 31115724
[TBL] [Abstract][Full Text] [Related]
15. Rosai-Dorfman-Destombes disease - histiocytic disorder with inflammatory manifestation.
Adam Z; Adamová Z; Pour L; Řehák Z; Koukalová R; Král Z
Klin Onkol; 2022; 35(4):262-170. PubMed ID: 35989082
[TBL] [Abstract][Full Text] [Related]
16. Pediatric Langerhans cell histiocytosis: the impact of mutational profile on clinical progression and late sequelae.
Nann D; Schneckenburger P; Steinhilber J; Metzler G; Beschorner R; Schwarze CP; Lang P; Handgretinger R; Fend F; Ebinger M; Bonzheim I
Ann Hematol; 2019 Jul; 98(7):1617-1626. PubMed ID: 30923995
[TBL] [Abstract][Full Text] [Related]
17. Mediastinal Rosai-Dorfman Disease with KRAS mutation case report and literature review.
Zhang W; Fang L; Wang J; Ma X; Hu X; Liu W
J Cardiothorac Surg; 2024 Apr; 19(1):166. PubMed ID: 38561747
[TBL] [Abstract][Full Text] [Related]
18. Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.
Jacobsen E; Shanmugam V; Jagannathan J
N Engl J Med; 2017 Dec; 377(24):2398-2399. PubMed ID: 29236635
[No Abstract] [Full Text] [Related]
19. [Cutaneous Rosai-Dorfman disease with lack of BRAF-V600, KRAS or NRAS mutations: A reactive or neoplastic disorder?].
Machado I; Alcacer Fernández-Coronado J; Requena C; Través V; Latorre Martínez N; Ortega J; Requena L; Alcacer García J
Rev Esp Patol; 2022; 55(1):52-56. PubMed ID: 34980442
[TBL] [Abstract][Full Text] [Related]
20. KRAS 117N positive Rosai-Dorfman disease with atypical features.
Jafri ZA; Reddy SP; Cassarino DS
J Cutan Pathol; 2021 Jan; 48(1):147-150. PubMed ID: 32974961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
